Donald A. Denkhaus is Director at CATALYST PHARMACEUTICALS, INC. (CPRX). They have made 12 open-market trades across 2 companies since 2008, most recently 2025-12-29.
CIK 0001278439
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
10 open-market purchases totalling $675K since 2008, against 2 sales. Across 10 scored buys the stock is up 16.7% at ninety days, and 12.4 points ahead of the S&P over the same stretch.
10 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 40% | 40% |
| Avg Move | -0.6% | +0.8% | +16.7% |
| Alpha | +1.0% | +0.2% | +12.4% |
| Scored | 10 | 10 | 10 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CPRX | SELL | 2022-11-11 | 2022-11-15 | $16.59 | $332K | +4.1% | +6.3% | -1.9% |
| CPRX | SELL | 2022-09-14 | 2022-09-15 | $15.34 | $307K | -5.1% | -0.2% | +35.4% |
| CPRX | BUY | 2018-12-27 | 2018-12-28 | $1.91 | $48K | +26.6% | +23.1% | +154.8% |
| CPRX | BUY | 2018-12-14 | 2018-12-17 | $2.48 | $149K | -18.9% | +6.1% | +26.2% |
| CPRX | BUY | 2018-06-08 | 2018-06-11 | $3.41 | $68K | -6.2% | -5.0% | -2.7% |
| CPRX | BUY | 2018-05-30 | 2018-05-31 | $3.75 | $75K | -12.3% | -15.2% | -21.9% |
| CPRX | BUY | 2016-06-14 | 2016-06-14 | $0.65 | $33K | +11.8% | +7.1% | +39.6% |
| CPRX | BUY | 2016-01-07 | 2016-01-07 | $2.03 | $102K | +5.3% | -19.3% | -39.6% |
| CPRX | BUY | 2015-04-30 | 2015-04-30 | $3.25 | $16K | -17.6% | -4.9% | -4.9% |
| CPRX | BUY | 2015-04-27 | 2015-04-28 | $3.71 | $56K | -17.6% | -4.9% | -4.9% |
| CPRX | BUY | 2015-03-27 | 2015-03-30 | $4.17 | $21K | -17.6% | -4.9% | -4.9% |
| NOVN | BUY | 2008-05-15 | 2008-05-19 | $10.90 | $109K | +40.1% | +25.7% | +25.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.